As the pharma companies are racing to develop the first coronavirus vaccine against the Covid-19 infection, German based biotech firm CureVac’s trial looks to be ahead with some promising results. The firm claimed that its coronavirus vaccine triggered an immune response in humans in the phase 1 trials, which means the mRNA vaccine is known to show protective response to virus sample injected in participants.
On the other hand, the United Kingdom has kickstarted boosting the review for AstraZeneca’s potential coronavirus vaccine to assess clinical data in real-time. The review of Pfizer Inc’s Covid-19 vaccine candidate has commenced too.
CEO Franz-Werner Haas termed the development as “encouraging.” For its potential vaccine, CureVac has incorporated the messenger RNA (mRNA) technique, pretty similar to Moderna, BioNtech and its partner Pfizer too.
The German firm has labelled its vaccine candidate ‘CVnCoV’ and is eyeing to enter the final stage of testing, comprising 30,000 participants, before the end of the year.
While AIIMS Delhi would submit a proposal to its ethics committee on Covaxin’s Phase III clinical trial data. Bharat Biotech, which has got approval from Drugs Controller General of India to conduct late-stage trials for Covaxin stated, it is keen to start recruitment and dosage for the Phase III trials in November and plans to launch the vaccine in second quarter of 2021.
Petition filed against NV Ramana’s accession to become CJI!